Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CDI-31244

Other · developed by Cocrystal Pharma

Phase 2 Most advanced trial (none active)
COCP Developer
1 Registered trials

What is CDI-31244?

CDI-31244 is a drug studied in chronic hepatitis C.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
Cocrystal Pharma, Inc. (COCP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03501550 Phase 2 Chronic Hepatitis C Completed COCP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis C

More from Cocrystal Pharma

CC-42344 Phase 2 CDI-988 Phase 1/2

Follow COCP, the company behind CDI-31244

See COCP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

COCP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.